Brief: Aldeyra Therapeutics Announces Clinical Development Plan For Resubmission Of New Drug Application For Reproxalap
28/03/2024 11:14
March 28 (Reuters) - Aldeyra Therapeutics Inc ALDX.O :
* ALDEYRA THERAPEUTICS ANNOUNCES CLINICAL DEVELOPMENT PLAN
FOR
RESUBMISSION OF NEW DRUG APPLICATION FOR REPROXALAP IN DRY EYE
DISEASE
* FOLLOWING DISCUSSIONS WITH FDA, INTENDS TO INITIATE A DRY
EYE
CHAMBER CLINICAL TRIAL IN FIRST HALF OF 2024
* NDA RESUBMISSION IS EXPECTED IN SECOND HALF OF 2024
Source text for Eikon: ID:nBw3fpKz6a
Further company coverage: ALDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aldeyra Therapeutics
See all newsBrief: Aldeyra Therapeutics Announces Intent To Submit Formal Dispute Resolution Request For Reproxalap To Treat Dry Eye Disease
Aldeyra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aldeyra Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Aldeyra Therapeutics Pays Off $15 Million Outstanding Borrowings, Terminates Hercules Credit Facility - SEC Filing
U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora